Consensus recommendation for meningococcal disease prevention in children and adolescents in the Middle East region

Atef Shibl; Haysam Tufenkeji; Mohamed Khalil; Ziad Memish

doi:10.1016/j.jegh.2012.02.002

<Previous Article In Issue

Next Article In Issue>

Volume 2, Issue 1, March 2012, Pages 23 - 30

Consensus recommendation for meningococcal disease prevention in children and adolescents in the Middle East region

Authors

Atef Shibl^a^{, *}^,amshibl@ksu.edu.sa amshibl1@yahoo.com, Haysam Tufenkeji^b, Mohamed Khalil^c, Ziad Memish^c, The Meningococcal Leadership Forum (“MLF”) Expert Group¹

^aKing Saud University, Riyadh, Saudi Arabia

^bKing Faisal Specialist Hospital & Research Centre, Saudi Arabia

^cMinistry of Health, Saudi Arabia

¹

See Appendix A for participants of “MLF” Expert Group in alphabetical order.

^*Corresponding author. Address: King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.

Corresponding Author

Atef Shiblamshibl@ksu.edu.sa amshibl1@yahoo.com

Received 21 October 2011, Revised 31 January 2012, Accepted 10 February 2012, Available Online 28 March 2012.

DOI: 10.1016/j.jegh.2012.02.002 How to use a DOI?
Keywords: Conjugate; Consensus recommendation; Invasive meningococcal disease; Middle East countries; Vaccine
Abstract: Facing the availability of the new generation of quadrivalent meningococcal conjugate vaccines (Menveo®, Menactra® and others pending for license) and their recent implementation in Saudi Arabia, experts from 11 countries of the Middle East region met at a “Meningococcal Leadership Forum” (MLF), which took place in May 2010 in Dubai. The participants of the conference discussed the importance of introducing the concept of conjugate vaccines – especially for children and adolescents – and elaborated a consensus recommendation to support healthcare professionals and decision makers with their expertise. In experts’ opinion, conjugate vaccines are the best choice for the prevention of meningococcal disease caused by serogroups A, C, W-135 and Y. As quadrivalent meningococcal conjugate vaccines are registered and available in the Middle East region, they should replace plain polysaccharide vaccines and be integrated in pediatric and adolescent vaccination schedules, including infant vaccination concomitantly with basic EPI vaccines when licensed.
Open Access: This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Download article (PDF)
View full text (HTML)

<Previous Article In Issue

Next Article In Issue>

Journal: Journal of Epidemiology and Global Health
Volume-Issue: 2 - 1
Pages: 23 - 30
Publication Date: 2012/03/28
ISSN (Online): 2210-6014
ISSN (Print): 2210-6006
DOI: 10.1016/j.jegh.2012.02.002 How to use a DOI?
Open Access: This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Cite this article

ris enw bib

TY  - JOUR
AU  - Atef Shibl
AU  - Haysam Tufenkeji
AU  - Mohamed Khalil
AU  - Ziad Memish
AU  - The Meningococcal Leadership Forum (“MLF”) Expert Group
PY  - 2012
DA  - 2012/03/28
TI  - Consensus recommendation for meningococcal disease prevention in children and adolescents in the Middle East region
JO  - Journal of Epidemiology and Global Health
SP  - 23
EP  - 30
VL  - 2
IS  - 1
SN  - 2210-6014
UR  - https://doi.org/10.1016/j.jegh.2012.02.002
DO  - 10.1016/j.jegh.2012.02.002
ID  - Shibl2012
ER  -

download .riscopy to clipboard